FindTrial
Sign In

BBI503

DRUG9 trials

Sponsors

Sumitomo Pharma America, Inc., Sumitomo Pharma Co., Ltd.

Conditions

Advanced Solid TumorsCancerCancer, Advanced Solid TumorsCholangiocarcinomaGastrointestinal Stromal TumorsHepatocellular CarcinomaOvarian CancerRenal Cell Carcinoma

Phase 1

A Study of BBI503 in Adult Patients With Advanced Solid Tumors
CompletedNCT01781455
Sumitomo Pharma America, Inc.Cancer, Advanced Solid Tumors
Start: 2012-02-29End: 2020-06-30Updated: 2023-11-14
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
CompletedNCT02279719
Sumitomo Pharma America, Inc.Hepatocellular Carcinoma
Start: 2014-12-31End: 2019-10-31Updated: 2023-11-15
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
CompletedNCT02354898
Sumitomo Pharma Co., Ltd.Advanced Solid Tumors, Hepatocellular Carcinoma
Start: 2015-03-31End: 2018-10-31Target: 60Updated: 2022-04-12
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
CompletedNCT02432326
Sumitomo Pharma America, Inc.Advanced Solid Tumors, Cancer
Start: 2015-04-30End: 2020-04-30Updated: 2023-11-08
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
CompletedNCT02483247
Sumitomo Pharma America, Inc.Cancer
Start: 2015-09-30End: 2019-05-31Updated: 2023-11-14

Phase 2

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
TerminatedNCT02232620
Sumitomo Pharma America, Inc.Gastrointestinal Stromal Tumors
Start: 2017-03-13End: 2017-07-25Updated: 2023-11-14
A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
WithdrawnNCT02232646
Sumitomo Pharma America, Inc.Renal Cell Carcinoma, Urologic Malignancies, Urothelial Carcinoma
Start: 2017-01-31End: 2018-08-01Updated: 2023-11-14
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
CompletedNCT02232633
Sumitomo Pharma America, Inc.Cholangiocarcinoma, Hepatocellular Carcinoma
Start: 2015-02-28End: 2017-12-14Updated: 2023-11-14
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
TerminatedNCT02432690
Sumitomo Pharma America, Inc.Cancer, Ovarian Cancer
Start: 2015-06-30End: 2017-01-02Updated: 2023-11-15

Related Papers

A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.
Journal of Clinical Oncology2017-05-208 citations
A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer.
Journal of Clinical Oncology2017-05-203 citations
Phase I extension clinical study of BB503, a first-in-class cancer stemness kinase inhibitor, in adult patients with advanced head and neck cancer.
Journal of Clinical Oncology2016-05-20
Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.
Journal of Clinical Oncology2015-05-204 citations
A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors.
Journal of Clinical Oncology2014-05-2014 citations